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Maraviroc (MVC), a C-C chemokine receptor type 5 (CCR5) antagonist, was approved as 
part of combination antiretroviral therapy (cART) in 2007, for use in treatment-experienced 
adults infected with CCR5-tropic HIV-1 [1]. Whilst with current treatment strategies such 
as maternal cART, low rates of mother-to-child transmission (MTCT) have been reported, 
in high-income countries, breastfeeding is not recommended because of the potential 
MTCT risk. However, since 2017, European [2] and US [3] guidelines have acknowledged 
that some HIV-infected women may wish to breastfeed, and should be given appropriate 
support in this decision. Whilst data exist describing the transfer of NRTI, NNRTI and PI 
to breastfed infants  [4-5], the pharmacokinetics and safety of MVC in lactating women and 
their breastfed infants have not been reported. Here, we present the first case of MVC in 
a breastfeeding mother. 
A 36-year-old perinatally HIV-1-infected woman received MVC (150 mg twice daily), 
lamivudine (150 mg twice daily) and lopinavir/ritonavir (400/100 mg twice daily). Her 
plasma HIV-RNA has remained undetectable with a CD4 count above 500 cells/µL on this 
regimen for over a decade.  
In 2018, at 38+4 weeks of gestation, she was delivered of a healthy girl (2710 g, 49 cm, 
head circumference 35 cm, APGAR score 10 at 5 minutes). Standard neonatal 
chemoprophylaxis with oral zidovudine (4 mg/kg twice daily) for fourteen days was given 
according to German-Austrian guidelines [6]. Although not recommended, breastfeeding 
was chosen. Exclusive breastfeeding continued until six months of age, with complete 
weaning by seven months. Clinical and laboratory assessment at two, four and eight 
weeks, and three, six, nine, and 12 months after birth revealed normal development. Full 
blood cell count, renal and liver parameters remained within normal range. HIV-DNA PCR 
results were consistently negative, and at twelve months of age, an HIV antibody test was 
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negative.  
At five months postpartum, a twelve-hour pharmacokinetic sampling of maternal plasma 
and breastmilk was performed to assess the breastmilk transfer and estimate infant 
exposure to MVC. After approval by the local ethics committee of the Charité University 
Medicine Berlin, the mother gave informed consent. Paired maternal plasma and 
breastmilk samples were obtained pre-dose (0 h), and 1, 2, 4, 6, 8, and 12 h following 
observed dosing. Thirteen days later, one single plasma sample from the still exclusively 
breast-fed infant was obtained during a routine follow-up visit. Samples were frozen at  
-30°C until shipment on dry ice to the laboratory (University of Liverpool, UK) for analysis. 
Plasma concentrations of MVC were determined by validated liquid chromatography 
tandem mass spectrometry method as previously described [7], with a modification for 
breastmilk. Briefly, the standards and quality control (QC) samples were prepared by 
spiking known concentration of drugs (TRC, Ontario, Canada) into breastmilk (donated by 
consenting volunteers through the UK Northwest Milkbank with ethics approval) to obtain 
a calibration curve (range 2.5 to 2500 ng/mL). MVC stable isotope was used as internal 
control to minimize matrix effect. 
Inter- and intra-day precision measured at the QC levels were 5.60% (3.71 – 6.72) and 
3.04% (2.00 – 4.40), respectively (Mean, range). Inter- and intra-day accuracy were 0.84% 
(-7.02 – 6.99) and 3.30% (-2.78 – 10.61), respectively. Mean recovery at all QC levels 
was 98.68% (SD, 5.69). 
The plasma MVC pharmacokinetic profile in the mother (Fig. 1) was comparable to 
published data of postpartum women [8], with full results reported in the figure legend. 
MVC was undetectable in the single infant sample. 
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A significant breastmilk transfer of MVC was demonstrated, with a milk-to-plasma (M:P) 
ratio of 0.61, consistent with studies in lactating rats which indicated that MVC is 
extensively secreted into rat milk [9]. MVC is licensed for children (two years and older) 
weighing at least 10 kg, at a starting dose of 50 mg. Assuming an infant milk intake of 150 
ml/kg/day, we estimate a daily MVC ingestion of less than 2 mg in this 6.5 kg infant. 
Concerns relating to breastmilk exposure of antiretroviral drugs relate to both infant toxicity 
and the potential for HIV drug resistance to develop, should MTCT occur in the presence 
of low drug concentrations. Although MVC was not detected in the infant, it should be 
noted that the lower limit of quantification of the assay (2.5 ng/mL) is above the IC90 (0.57 
ng/mL) [10]; low, but clinically relevant infant concentrations were possible. Data from a 
single case must be interpreted with caution and more data regarding MVC in 
breastfeeding mother-infant pairs are needed.  
In conclusion, there is significant penetration of MVC into breastmilk with a M:P ratio of 
0.61, but MVC was undetectable in the breastfed infant. 
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Figure1 Click here to access/download;Figure;MVC plasma and BM 3.jpg
Fig. 1. Maraviroc maternal plasma and breastmilk concentration time-profiles at 
five months postpartum. Maraviroc concentrations in plasma and breastmilk 
measured by validated liquid chromatography tandem mass spectrometry as 
described in the case report. The AUC0-12 h for maraviroc in plasma was 3790 
h*ng/mL with a Cmax of 780 ng/mL reached after 1 hour. The breastmilk AUC0-12 h was 
2317 h*ng/mL with a Cmax of 415 ng/mL reached after 2 hours. The milk-to-plasma 
(M:P) ratio of AUC0-12 h was 0.61. 
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